# DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference
Ticker: DMAC
Company: DiaMedica Therapeutics
Source: DiaMedica Therapeutics
Published: 2026-05-12 20:15 EST
Original Source URL: https://www.diamedica.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-17 20:30 EST — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-06-23 12:30 EST — [DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199--97b3dc71) — Source: DiaMedica Therapeutics
- 2026-06-16 12:30 EST — [DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program](https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program-34bd4bf5) — Source: DiaMedica Therapeutics
- 2026-05-27 20:30 EST — [DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026) — Source: DiaMedica Therapeutics
- 2026-05-20 12:30 EST — [DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-75-enrollment-milestone-in-remedy2-phase-2-3-acute-ischemic-stroke-trial) — Source: DiaMedica Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)